贝利尤单抗对狼疮性肾炎肾脏结局的影响:BLISS-LN 3期试验的事后亚组分析
BLISS-LN 3期随机双盲试验事后分析纳入448例活动性狼疮性肾炎患者,评估贝利尤单抗对新诊断和复发亚组及诱导期是否使用糖皮质激素冲击患者的肾脏结局。结果显示贝利尤单抗在多个亚组中与安慰剂相比有更高的肾脏缓解比例,且肾脏相关事件或死亡、狼疮 flare 概率更低。
要点
- 新诊断亚组中贝利尤单抗组 PERR 46.6% vs 安慰剂组 37.2%(OR 1.36,95%CI 0.85-2.20)。
- 复发亚组中贝利尤单抗组 PERR 36.0% vs 安慰剂组 22.7%(OR 2.31,95%CI 1.07-5.01)。
- 无论诱导期是否使用糖皮质激素冲击,贝利尤单抗均与安慰剂相比改善肾脏结局。
核心结论
- 数据提示贝利尤单抗对新诊断和复发狼疮性肾炎患者的肾脏结局有一致获益,且与诱导期是否使用糖皮质激素冲击无关。
研究设计与样本
- BLISS-LN 为3期随机双盲研究(GSK BEL114054;NCT01639339),共随机448例活动性狼疮性肾炎患者。
- 事后分析按新诊断/复发亚组及诱导期是否使用糖皮质激素冲击评估贝利尤单抗(每月静脉10 mg/kg)或安慰剂联合标准治疗的疗效。
主要发现
- 第104周 PERR:新诊断亚组贝利尤单抗组 69/148(46.6%)vs 安慰剂组 55/148(37.2%),OR 1.36(95%CI 0.85-2.20)。
- 第104周 PERR:复发亚组贝利尤单抗组 27/75(36.0%)vs 安慰剂组 17/75(22.7%),OR 2.31(95%CI 1.07-5.01)。
- 第104周 CRR:新诊断亚组贝利尤单抗组 50/148(33.8%)vs 安慰剂组 36/148(24.3%),OR 1.49(95%CI 0.88-2.51)。
- 第104周 CRR:复发亚组贝利尤单抗组 17/75(22.7%)vs 安慰剂组 8/75(10.7%),OR 3.11(95%CI 1.16-8.31)。
- 两个亚组中贝利尤单抗组与安慰剂组相比肾脏相关事件或死亡、以及自第24周起首次狼疮 flare 的概率均更低。
关键数值与推荐
- PERR 新诊断:贝利尤单抗 46.6% vs 安慰剂 37.2%(OR 1.36,95%CI 0.85-2.20)。
- PERR 复发:贝利尤单抗 36.0% vs 安慰剂 22.7%(OR 2.31,95%CI 1.07-5.01)。
- CRR 新诊断:贝利尤单抗 33.8% vs 安慰剂 24.3%(OR 1.49,95%CI 0.88-2.51)。
- CRR 复发:贝利尤单抗 22.7% vs 安慰剂 10.7%(OR 3.11,95%CI 1.16-8.31)。
临床怎么用
- 贝利尤单抗(每月静脉10 mg/kg)联合标准治疗在新诊断和复发狼疮性肾炎患者中及无论诱导期是否使用糖皮质激素冲击均与肾脏结局改善相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on belimumab efficacy in patients with lupus nephritis (LN) according to diagnosis duration or induction therapy are limited. Post hoc analyses of the phase 3, randomized, double-blind BLISS-LN study (GSK BEL114054; NCT01639339) were performed to assess belimumab efficacy on kidney-related outcomes in newly diagnosed and relapsed LN subgroups and according to the use of glucocorticoid (GC) pulses at induction. METHODS: BLISS-LN randomized 448 patients with active LN to monthly intravenous belimumab 10 mg/kg or placebo plus standard therapy. Post hoc analyses assessed primary efficacy renal response (PERR) and complete renal response (CRR) at week 104, time to kidney-related event or death and time to first LN flare from week 24 in newly diagnosed and relapsed patients and patients with/without GC pulses at induction. RESULTS: A greater proportion of patients achieved a PERR with belimumab versus placebo in the newly diagnosed {69/148 [46.6%] versus 55/148 [37.2%]; odds ratio [OR] 1.36 [95% confidence interval (CI) 0.85-2.20]} and relapsed [27/75 (36.0%) versus 17/75 (22.7%); OR 2.31 (95% CI 1.07-5.01)] subgroups. Similarly for CRR [newly diagnosed: 50/148 (33.8%) versus 36/148 (24.3%); OR 1.49 (95% CI 0.88-2.51) and relapsed: 17/75 (22.7%) versus 8/75 (10.7%); OR 3.11 (95% CI 1.16-8.31)]. The probability of kidney-related event or death, or LN flare was lower with belimumab versus placebo in both subgroups. Belimumab was associated with improved kidney outcomes versus placebo with or without GC pulses at induction. CONCLUSION: Data suggest consistent benefits of belimumab on kidney outcomes for newly diagnosed and relapsed patients, and irrespective of GC pulses at induction.
引用
- Anders HJ, Furie R, Malvar A, et al. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Nephrol Dial Transplant. 2023. PMID: 37463054. doi:10.1093/ndt/gfad167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。